Clinical Trial

A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

Completed Phase 4
View on ClinicalTrials.gov →
Summary
This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.
Protocol Amendment History 1 change
critical Trial completed 2026-07-11
Trial Details
NCT Number NCT06716424
Lead Sponsor Sanofi
Conditions Type 2 Diabetes
Enrollment 105 participants
Start Date 2025-01-06
Primary Completion 2026-06-12 (estimated)
Study Completion 2026-06-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-10